Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 6/20 | 0.58 |
| ▸ | BRD2 | P25440 | 2/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872994 | 0.83 | HTT (0.56) | HTTMAPK1ALDH1A1TP53LMNA | |
| SCHEMBL2875807 | 0.82 | ALDH1A1 (0.61) | HTTMAPK1BRD4ALDH1A1TP53 | |
| SCHEMBL4657372 | 0.82 | BRD4 (0.58) | HTTBRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL5622378 | 0.82 | TP53 (0.74) | HTTBRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL2444259 | 0.80 | CA1 (0.51) | HTTMAPK1BRD4BRD2BRD3 | |
| SCHEMBL5504038 | 0.79 | ALDH1A1 (0.61) | HTTMAPK1ALDH1A1TP53LMNA | |
| SCHEMBL128275 | 0.78 | ALDH1A1 (0.64) | HTTBRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL18739953 | 0.78 | BRD4 (0.54) | HTTBRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL23613810 | 0.77 | SMN1; SMN2 (0.69) | HTTBRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL16225504 | 0.77 | MEN1 (0.68) | HTTMAPK1ALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146770-A | 2-phenyl indoles as prostaglandin D2 receptor antagonists | AVENTIS PHARMA INC (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | HTT 3945/4885MAPK1 3444/4885BRD4 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.